DIRS.INFO The most relevant business & tech news

☆ These stocks are close to forming the dreaded death cross pattern
▼ + stars: | 2024-06-12 | by ( Brian Evans | ) www.cnbc.com time to read: +2 min

CNBC screened for stocks that were on the verge of forming a dreaded death cross chart pattern. A death cross occurs when a stock's 50-day moving average slips below its downward-trending 200-day counterpart. Northrop Grumman Aerospace and defense stock Northrop Grumman has pulled back roughly 9% in 2024 and is closing in on a death cross chart pattern. The stock's 50-day moving average broke above its 200-day counterpart earlier this year, a short-lived sign of improving momentum. Other stocks on the list signaling a death cross chart pattern include Pool Corporation and Fortive Corporation .

Persons: Dow Jones, Northrop Grumman, Northrop, Zimmer, Zimmer Biomet, IDEX, —, Nick Wells Organizations: Nasdaq, Federal, CNBC, Northrop Grumman Aerospace, . Navy, Zimmer Biomet Holdings, IDEX Corporation Laboratory, Corporation, Fortive Corporation

Hans Zimmer Live 2024 is the sixth official touring production in which the famous composer performs live onstage. We've got you covered if you're looking for how to get tickets to Hans Zimmer Live 2024. Hans Zimmer 2024 tour scheduleHans Zimmer has 17 shows confirmed for the North American portion of his 2024 tour, taking him across just as many cities in the United States and Canada. Standard tickets for Hans Zimmer Live on verified resale sites are generally comparable to or less expensive than original ticket prices. Three international dates for Hans Zimmer Live 2024's North American leg are also confirmed.

Persons: Hans Zimmer, he's, King, Christopher Nolan's, Denis Velleneuve's, Zimmer, We've, Hans Zimmer's, Zimmer's Organizations: Business, United, Pirates, Ticketmaster, North, Zimmer's, Odessa Orchestra & Friends, Choir Locations: United States, American, Caribbean, North America, Canada, Duluth , Georgia, Vancouver , British Columbia, York City, Duluth, Hollywood, Raleigh, NC, NY, Baltimore, Boston, Montreal, Toronto, ON, Minneapolis, Chicago, Fort Worth , TX, Denver, Vegas, Los Angeles, CA, Oakland, Seattle, WA, Vancouver, BC, North American, Zimmer's Raleigh, Las Vegas, Dubai, Dortmund, Germany, British Columbia

☆ An academic analyzed everything Mark Zuckerberg said publicly for 20 years — but still doesn't feel like he knows him
▼ + stars: | 2024-01-15 | by ( Hasan Chowdhury | ) www.businessinsider.com time to read: +6 min

The academic launched the project after the Meta boss discussed privacy issues in interviews. AdvertisementA lot has changed for Mark Zuckerberg since the drunken night at Harvard in 2003 when he decided to release Facemash. Mark Zuckerberg is CEO of Facebook owner Meta. "The Zuckerberg Files came out of a project where I was thinking about how Zuckerberg talks about privacy," Zimmer explained in the documentary. Zimmer thinks the exhaustive project has been "really insightful" in helping track the maturity of both Zuckerberg and his company.

Persons: Michael Zimmer, Mark Zuckerberg's, intentensly, Zimmer, —, Mark Zuckerberg, Zuckerberg, Meta, Kevin Dietsch, David Kirkpatrick, Sheera Frenkel, Kara Swisher, He's, he's, Elon Musk Organizations: Service, Harvard, Facebook, Zuckerberg, San Francisco Chronicle, Capitol, Cambridge, Meta Locations: Marquette, Hawaii

☆ Medical device maker Zimmer cuts revenue growth forecast as profit beats
▼ + stars: | 2023-11-07 | by ( ) www.reuters.com time to read: +2 min

Sales at Zimmer's knees unit rose 7.5% to $706.3 million, compared to analysts' estimate of $702.9 million. That helped cushion a miss at its hips unit, where sales of $465.3 million compared with estimates of $481.7 million. The Indiana-based company's third-quarter revenue rose 5% to $1.75 billion, in line with analysts' average estimates. Zimmer had said earlier that it expects second- and third-quarter revenue to be a "little bit lighter" compared to the first quarter. The hip and knee implant maker cut its full-year reported revenue forecast to a growth of 6% to 6.5% from 6.5% to 7.0% earlier while backing its full-year profit forecast of $7.47 to $7.57 per share.

Persons: Zimmer Biomet, Moritz Hager, Zimmer, Johnson, Ivan Tornos, Christy Santhosh, Sriraj Organizations: REUTERS, Zimmer Biomet Holdings, Laboratories, Boston, Thomson Locations: Winterthur, Switzerland, Indiana, Bengaluru

☆ Medical device maker Zimmer Biomet lifts profit forecast as surgeries rebound
▼ + stars: | 2023-08-01 | by ( ) www.reuters.com time to read: +1 min

Aug 1 (Reuters) - Zimmer Biomet Holdings Inc (ZBH.N) on Tuesday raised its full-year profit forecast, anticipating demand to hold up for its medical devices following a rebound in knee and hip replacement procedures. Abbott Laboratories (ABT.N) attributed its strong quarter to hospitals addressing bottlenecks from the pandemic while Johnson & Johnson (JNJ.N) said it expected to top profit estimates with surgeries bouncing back. The company now expects full-year profit of $7.47 to $7.57 per share, compared with its previous forecast of $7.40 to $7.50. The Indiana-based company's second-quarter revenue rose nearly 5% to $1.87 billion, beating analysts' estimates of $1.83 billion. Zimmer also expects reported revenue to grow between 6.5% and 7% this year, compared to its prior forecast of between 5% and 6%.

Persons: Zimmer, Johnson, Jeff Johnson, Mariam Sunny, Sriraj Organizations: Zimmer Biomet Holdings, Abbott Laboratories, Baird Equity, Thomson Locations: Indiana, Bengaluru

☆ Zimmer Biomet raises annual forecasts on knees and hips unit strength
▼ + stars: | 2023-05-02 | by ( ) www.reuters.com time to read: +2 min

[1/2] The logo of medical implants maker Zimmer Biomet is seen at a plant in Winterthur, Switzerland, November 16, 2018. REUTERS/Moritz HagerMay 2 (Reuters) - Zimmer Biomet Holdings Inc (ZBH.N) raised its annual sales and profit forecasts on Tuesday, banking on strong demand for its knees and hips products amid a sustained recovery in surgical procedures in the United States. Shares of the Indiana-based medical device maker rose 3.72% to $144 before the bell, also buoyed by better-than-expected first-quarter results. Zimmer Biomet's upbeat outlook comes after several medical device makers, including Stryker Corp (SYK.N) and larger rival Abbott Laboratories (ABT.N), raised their forecasts as easing staffing shortages at hospitals aid a recovery in medical procedures. The medical device maker's revenue rose 10% to $1.83 billion in the first quarter, beating analysts' average estimates of $1.70 billion.

Search resuls for: "Zimmer's"

6 mentions found